(Q34121339)

31 July 2017

1 reference

title

Novel dual Src/Abl inhibitors for hematologic and solid malignancies (English)

1 reference

31 July 2017

4

Maurizio Botta

1 reference

31 July 2017

Silvia Schenone

1

1 reference

31 July 2017

Chiara Brullo

series ordinal

2

1 reference

31 July 2017

Francesca Musumeci

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

931-945

1 reference

Role of Src expression and activation in human cancer

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Synthetic SRC-kinase domain inhibitors and their structural requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Last findings on dual inhibitors of abl and SRC tyrosine-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Treatment selection after imatinib resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

New approved dasatinib regimen available for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

A once-daily dasatinib dosing strategy for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Src as a therapeutic target in men with prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

New developments in multitargeted therapy for patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Target profiling of small molecules by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Systems biology in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Predicting drug side-effects by chemical systems biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

Network analyses in systems pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499898

10.1517/13543784.2010.499898

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference